SCHEMBL23810985

SCHEMBL23810985

CC(C)(C)OC(=O)COc1ccc(Br)cc1CO

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 5/20 0.65
ALDH1A1 P00352 4/20 0.55
MAPT P10636 2/20 0.55
LMNA P02545 1/20 0.55
NPC1 O15118 4/20 0.54
MAPK1 P28482 2/20 0.52
HSD17B10 Q99714 2/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.42
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
AAK1 Q2M2I8 3/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CCR5 P51681 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27833990 0.83 MAPT (0.65) PTGDR2ALDH1A1MAPTLMNAHSD17B10
SCHEMBL28979210 0.83 AAK1 (0.56) PTGDR2ALDH1A1LMNANPC1MAPK1
SCHEMBL31426280 0.82 PTGDR2 (0.57) PTGDR2ALDH1A1MAPTNPC1MAPK1
SCHEMBL24933585 0.82 AAK1 (0.57) PTGDR2ALDH1A1MAPTLMNANPC1
SCHEMBL13903612 0.82 PTGDR2 (0.67) PTGDR2ALDH1A1MAPTLMNANPC1
SCHEMBL24934111 0.82 MTNR1A (0.50) PTGDR2ALDH1A1NPC1MAPK1MEN1
SCHEMBL1370592 0.82 PTGDR2 (0.49) PTGDR2ALDH1A1MAPTNPC1MAPK1
SCHEMBL20063716 0.82 KMT2A (0.59) PTGDR2ALDH1A1MAPTLMNANPC1
SCHEMBL5561274 0.81 PTGDR2 (0.43) PTGDR2ALDH1A1MAPTLMNANPC1
SCHEMBL13140904 0.80 L3MBTL1 (0.45) ALDH1A1MAPTHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112543764-B Amide compound with BET proteolytic induction effect and medical application thereof 田边三菱制药株式会社 2024-05-10 CN disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB PTGDR2 4214/4885ALDH1A1 4054/4885MAPT 3109/4885
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF BET1, BRD4, PHKB PTGDR2 4236/4885ALDH1A1 4055/4885MAPT 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.